|Application ||WB, IHC-P, IF, FC, E|
|Calculated MW||53652 Da|
|Other Names||Vimentin, VIM|
|Target/Specificity||This Vimentin antibody is generated from rabbits immunized with human Vimentin recombinant protein.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Precautions||Vimentin Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally.|
|Tissue Location||Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone- independent mammary carcinoma cell lines|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the intermediate filament family. Intermediate filamentents, along with microtubules and actin microfilaments, make up the cytoskeleton. The protein encoded by this gene is responsible for maintaining cell shape, integrity of the cytoplasm, and stabilizing cytoskeletal interactions. It is also involved in the immune response, and controls the transport of low-density lipoprotein (LDL)-derived cholesterol from a lysosome to the site of esterification. It functions as an organizer of a number of critical proteins involved in attachment, migration, and cell signaling. Mutations in this gene causes a dominant, pulverulent cataract.
Kers, J., et al. Transplantation 90(5):502-509(2010)
Pinheiro, A.P., et al. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B (5), 1070-1080 (2010) :
Korita, P.V., et al. Anticancer Res. 30(6):2279-2285(2010)
Martins-de-Souza, D., et al. J Psychiatr Res (2010) In press :
Li, M., et al. J. Exp. Clin. Cancer Res. 29, 109 (2010) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.